Possible acute rejection associated with the use of the new antihepatitis C virus medications

Abstract

Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new direct-acting antiviral agents gave big hopes to both clinicians and patients that they can overcome this challenge without major side effects. Studies recently have supported this claim; however, they are still few, limited, and may give false hopes. In the following case report, we present a case, supported by histological evidence about a possible acute rejection of kidney transplant after treatment with these new medications. This case is limited by the absence of donor-specific antibodies. This report is aimed to increase awareness about the urgent need for further studies.

Specific MiRNAs in naïve T cells associated with Hepatitis C Virus-induced Hepatocellular Carcinoma

“…1 E). For example, consistent with the known finding that HCV infection may cause the acute rejection of transplanted kidneys 42 , the increased proportion of C06_CD4-CCR7 in HCV-HCC was also shown to be involved in allograft rejection.…”

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

“…This includes the necessity of HCV antiviral therapy and the risk of liver disease if such treatment is unavailable or unsuccessful. Additionally, there is a risk of DAA-associated allograft rejection and possible loss, (356)(357)(358)(359)(360)(361)(362) and/or reduced allograft function. (361,(363)(364)(365)(366) Because use of allografts from HCV-viremic donors in HCV-negative recipients is a recent development in transplant medicine, there are no data on possible long-term hepatic and extrahepatic adverse effects associated with HCV exposure, even among those cured of the infection.…”

Transplanting Organs from Donors with HIV or Hepatitis C: The Viral Frontier

“…Treatment regimens are varied, and further research is needed regarding timing and interactions with long-term outcomes. Furthermore, it is important to educate patients that there are potential risks of DAA-associated organ rejection, poor graft function, and sexual transmission to their partner [80][81][82][83].…”